Accéder au contenu
Merck
  • Identification of epithelial stromal interaction 1 as a novel effector downstream of Krüppel-like factor 8 in breast cancer invasion and metastasis.

Identification of epithelial stromal interaction 1 as a novel effector downstream of Krüppel-like factor 8 in breast cancer invasion and metastasis.

Oncogene (2013-10-08)
T Li, H Lu, C Shen, S K Lahiri, M S Wason, D Mukherjee, L Yu, J Zhao
RÉSUMÉ

Krüppel-like factor 8 (KLF8) is a transcriptional factor critical for metastatic progression of breast cancer. Epithelial stromal interaction 1 (EPSTI1), a recently identified stromal fibroblast-induced gene in non-invasive breast cancer cells is highly overexpressed in invasive breast carcinomas. The function and regulation of EPSTI1, however, remain largely unknown. In this paper, we report a novel KLF8 to EPSTI1 signaling pathway in breast cancer. Using various expression analyses, we revealed a high co-overexpression of KLF8 and EPSTI1 in invasive human breast cancer cells and patient tumors. Ectopic overexpression of KLF8 in the non-invasive MCF-10A cells induced the EPSTI1 expression, whereas KLF8 knockdown from the invasive, MDA-MB-231 cells decreased the EPSTI1 expression. Promoter activation and binding analyses indicated that KLF8 promoted the EPSTI1 expression by directly acting on the EPSTI1 gene promoter. EPSTI1 knockdown dramatically reduced the KLF8-promoted MCF-10A cell invasion, and ectopic expression of EPSTI1 in the non-invasive MCF-7 cells is sufficient to induce the cell invasion. Experiments using nude mice demonstrated that the ectopic EPSTI1 granted the MCF-7 cells capability of both invasive growth in the breasts and metastasis to the lungs. Using co-immunoprecipitation coupled with mass spectrometry, we discovered that EPSTI1 interacts with the valosin-containing protein (VCP), resulting in the degradation of IκBα and subsequent activation of NF-κB in the nucleus. These findings suggest a novel KLF8 to EPSTI1 to VCP to NF-κB signaling mechanism potentially critical for breast cancer invasion and metastasis.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Formaldéhyde solution, for molecular biology, 36.5-38% in H2O
Sigma-Aldrich
o-xylène, puriss. p.a., ≥99.0% (GC)
Sigma-Aldrich
o-xylène, reagent grade, ≥98.0%
Sigma-Aldrich
Acide éthylènediaminetétraacétique solution, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Ethylenediaminetetraacetic acid, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
Ethylenediaminetetraacetic acid, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
Ethylenediaminetetraacetic acid, 99.995% trace metals basis
Sigma-Aldrich
Hematoxylin
Sigma-Aldrich
Acide éthylènediaminetétraacétique disodium salt solution, BioUltra, for molecular biology, pH 8.0, ~0.5 M in H2O
Supelco
o-xylène, suitable for HPLC, 98%
Sigma-Aldrich
Ethylenediaminetetraacetic acid, anhydrous, BioUltra, ≥99% (titration)
Sigma-Aldrich
Hematoxylin, certified by the Biological Stain Commission
Sigma-Aldrich
Ethylenediaminetetraacetic acid, purified grade, ≥98.5%, powder
Sigma-Aldrich
Eosin Y, Dye content ~99 %
Sigma-Aldrich
Eosin Y solution, 5 wt. % in H2O
Sigma-Aldrich
Eosin Y disodium salt, Dye content ≥85 %
Sigma-Aldrich
Eosin Y disodium salt, certified by the Biological Stain Commission
Sigma-Aldrich
o-xylène, anhydrous, 97%
Supelco
o-xylène, analytical standard
Sigma-Aldrich
Eosin Y, 75% (HPLC)
Sigma-Aldrich
Ethylenediaminetetraacetic acid, ≥98.0% (KT)
Sigma-Aldrich
Ethylenediaminetetraacetic acid, BioUltra, ≥99.0% (KT)
Millipore
Anti-HA Immunoprecipitation Kit
Supelco
o-xylène, Pharmaceutical Secondary Standard; Certified Reference Material